This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jaffe, R. Articles by Strauss, B. H. Search for Related Content PubMed Articles by Jaffe, R. Articles by Strauss, B. H.

Prevention and Treatment of Microvascular Obstruction-Related Myocardial Injury and Coronary No-Reflow Following Percutaneous Coronary Intervention

A Systematic Approach

Ronen Jaffe, MD^_*,_*, Alexander Dick, MD, Bradley H. Strauss, MD, PhD

^_* Lady Davis Medical Center, Department of Cardiology, Haifa, Israel
Schulich Heart Programme, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

^_* Reprint requests and correspondence: Dr. Ronen Jaffe, Cardiology Department, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel (Email: jaffe{at}clalit.org.il).

Microvascular obstruction (MVO) commonly occurs following percutaneous coronary interventions (PCI), may lead to myocardial injury, and is an independent predictor of adverse outcome. Severe MVO may manifest angiographically as reduced flow in the patent upstream epicardial arteries, a situation that is termed "no-reflow." Microvascular obstruction can be broadly categorized according to the duration of myocardial ischemia preceding PCI. In "interventional MVO" (e.g., elective PCI), obstruction typically involves myocardium that was not exposed to acute ischemia before PCI. Conversely "reperfusion MVO" (e.g., primary PCI for acute myocardial infarction) occurs within a myocardial territory that was ischemic before the coronary intervention. Interventional and reperfusion MVO have distinct pathophysiological mechanisms and may require individualized therapeutic approaches. Interventional MVO is triggered predominantly by downstream embolization of atherosclerotic material from the epicardial vessel wall into the distal microvasculature. Reperfusion MVO results from both distal embolization and ischemia-reperfusion injury within the subtended ischemic tissue. Management of MVO and no-reflow may be targeted at different levels: the epicardial artery, microvasculature, and tissue. The aim of the present report is to advocate a systematic approach to prevention and treatment of MVO in different clinical settings. Randomized clinical trials have studied strategies for prevention of MVO and no-reflow; however, the efficacy of measures for reversing MVO once no-reflow has been demonstrated angiographically is unclear. New approaches for prevention and treatment of MVO will require a better understanding of intracellular cardioprotective pathways such as the blockade of the mitochondrial permeability transition pore.

Key Words: no-reflow • microvascular obstruction • coronary intervention • distal embolization • cardioprotection

Abbreviations and Acronyms   ACC = American College of Cardiology   AHA = American Heart Association   MPTP = mitochondrial permeability transition pore   MVO = microvascular obstruction   PCI = percutaneous coronary interventions